Cargando…

The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies targeting cellular adhesion molecules. While IgE autoantibodies are occasionally reported in other autoimmune blistering diseases, BP is unique in that most BP patients develop an IgE autoantibody response. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messingham, Kelly N., Crowe, Tyler P., Fairley, Janet A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787172/ https://www.ncbi.nlm.nih.gov/pubmed/31636640 http://dx.doi.org/10.3389/fimmu.2019.02331

Ejemplares similares

Human Eosinophils Express the High Affinity IgE Receptor, FcεRI, in Bullous Pemphigoid
por: Messingham, Kelly N., et al.
Publicado: (2014)

IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients
por: Lamberts, A., et al.
Publicado: (2020)

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2019)

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review
por: Saniklidou, Ariadne Hadjikyriacou, et al.
Publicado: (2017)

Elevated levels of sCD48 are inversely correlated with markers of disease activity in bullous pemphigoid
por: Treco, Emma, et al.
Publicado: (2022)

Explosive bullous pemphigoid with high serum total IgE: Serum IgE as a biomarker that reflects disease activity
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

IgE glycans promote anti-IgE IgG autoantibodies that facilitate IgE serum clearance via Fc Receptors
por: Plattner, Kevin, et al.
Publicado: (2022)

Bullous pemphigoid associated with milia, increased serum IgE, autoantibodies against desmogleins, and refractory treatment in a young patient
por: Ding, Shu, et al.
Publicado: (2017)

New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update
por: Genovese, Giovanni, et al.
Publicado: (2019)

Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients
por: Chiorean, Roxana M., et al.
Publicado: (2018)

Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms
por: Cole, Connor, et al.
Publicado: (2022)

Adaptive and innate immune pathogenesis of bullous pemphigoid: A review
por: Yan, Tianmeng, et al.
Publicado: (2023)

IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants
por: Freire, P.C., et al.
Publicado: (2017)

Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy
por: Wright, Benjamin L., et al.
Publicado: (2018)

Biological treatment for bullous pemphigoid
por: Oren-Shabtai, Meital, et al.
Publicado: (2023)

Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid
por: Koga, Hiroshi, et al.
Publicado: (2023)

Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity
por: Farnaghi, Farshad, et al.
Publicado: (2020)

The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury
por: Fang, Hui, et al.
Publicado: (2018)

Autoantibodies Against the Immunodominant Bullous Pemphigoid Epitopes Are Rare in Patients With Dermatitis Herpetiformis and Coeliac Disease
por: Nätynki, Antti, et al.
Publicado: (2020)

Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody
por: Clapé, Ariane, et al.
Publicado: (2018)

Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy
por: Zhang, Luyao, et al.
Publicado: (2023)

IgG/IgE bullous pemphigoid with CD45 lymphocytic reactivity to dermal blood vessels, nerves and eccrine sweat glands
por: Abreu-Velez, Ana Maria, et al.
Publicado: (2010)

Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid
por: Cole, Connor, et al.
Publicado: (2022)

Relevance of Eosinophilia and Hyper-IgE in Immigrant Children
por: Belhassen-García, Moncef, et al.
Publicado: (2014)

BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid
por: Liu, Yale, et al.
Publicado: (2017)

Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid
por: Tabatabaei-Panah, Pardis-Sadat, et al.
Publicado: (2019)

Case Report: The many faces of bullous pemphigoid
por: Rechtien, Laura, et al.
Publicado: (2023)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans
por: Russlies, Juliane, et al.
Publicado: (2019)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021)

Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid
por: Zhou, Tong, et al.
Publicado: (2021)

Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid
por: Rosi-Schumacher, Mattie, et al.
Publicado: (2023)

Comorbidity in bullous pemphigoid: up-date and clinical implications
por: Huttelmaier, Johanna, et al.
Publicado: (2023)

A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry
por: Lee, Janet, et al.
Publicado: (2019)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid
por: Chen, Jia, et al.
Publicado: (2020)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Wang, Si-Hang, et al.
Publicado: (2021)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2021)

Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics
por: Zhang, Jie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_usiqcb61bkf213f41d798is6td